DC Chemicals · Product datasheet

Fenretinide (4-HPR) — Datasheet

CAT. NO. DC7714

Product page and current package options

ParameterValue
Chemical NameFenretinide
CAS No.65646-68-6
SynonymsFenretinide;N-(4-Hydroxyphenyl)retinamide;Retinoic acid p-hydroxyanilide;all-trans-N-(4-Hydroxyphenyl)retinamide;4-HYDROXYPHENYLRETINAMIDE;Retinamide,N-(4-hydroxyphenyl)-;(4-Hydroxyphenyl)retinamide;4-HPR;Fenretinide(4-HPR);4-Hydroxyphenyl retinamide;all-trans-4'-Hydroxyretinanilide;Fenretinidum;Fenretinida;4-hydroxy(phenyl)retinamide;N-(4-Hydroxyphenyl)all-Trans Retinamide;Fenretinidum [Latin];Fenretinida [Spanish];4HPR;Retinoic acid p-hydroxyphenylamide;Fenretinide [USAN:INN];Retinamide, N-(4-hydroxyphenyl)-;4-(hydroxyphenyl)retinamide;15-[(4-hydroxyphenyl)amino]retinal;CC
FormulaC26H33NO2
M.Wt391.5457
SMILESO=C(/C(/[H])=C(\C([H])([H])[H])/C(/[H])=C(\[H])/C(/[H])=C(\C([H])([H])[H])/C(/[H])=C(\[H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])N([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H]
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.

In Vitro

Fenretinide exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells[1]. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake[2]. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates[4].

In Vivo

Fenretinide (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests[2]. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels[3].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation